omatic patients
with 50% or greater stenosis and severe uncorrectable coronary artery disease, congestive heart failure, or chronic obstructive pulmonary disease. The
committee recognized the difﬁculty in clearly
deﬁning this group of individuals, both in symptomatology and risk assessment, and acknowledged the
potential increased role of aggressive medical management as primary therapy in this high-risk group
(Table II).
8. Neurologically asymptomatic patients deemed high
risk for CEA